| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| Other Sizes |
| Targets |
The compound acts as an anti-inflammatory agent by suppressing prostaglandin E2 (PGE2) and inflammatory cytokines (IL-6, IL-8). It has demonstrated protein-ligand interactions with SARS-CoV-2 main protease (PDB code: 6yb7) and DHFR through molecular docking and in vitro assays, suggesting potential antiviral and antidiabetic activities.
|
|---|---|
| ln Vitro |
In vitro, 4-Ethoxybenzaldehyde (1%) added to water-in-oil emulsions significantly and safely reduces facial erythema. It suppresses UVR-induced production of PGE2, IL-6, and IL-8. It shows anti-inflammatory and antidiabetic activities in protein-ligand interaction studies. It may also act as a DHFR inhibitor.
|
| ln Vivo |
In vivo, 4-Ethoxybenzaldehyde has demonstrated anti-inflammatory and antidiabetic activity in animal models. When formulated in emulsions at 1% concentration, it effectively reduces UVR-induced facial erythema. The compound shows promising results as a skin-lightening and anti-inflammatory agent in clinical studies on facial erythema and hyperpigmentation.
|
| Enzyme Assay |
The compound (1-100 uM) is dissolved in appropriate buffer (e.g., PBS, pH 7.4). For enzyme inhibition assays, target enzyme (e.g., DHFR, SARS-CoV-2 main protease) is pre-incubated with compound at 25-37degC for 15-60 minutes. Substrate is added, and enzyme activity is measured spectrophotometrically. Molecular docking (e.g., AutoDock) confirms binding modes and interaction energies.
|
| Cell Assay |
Human keratinocytes or skin fibroblasts are cultured in DMEM with 10% FBS and 1% PS at 37degC, 5% CO2. Cells are treated with 4-Ethoxybenzaldehyde (1-100 uM) for 24-48 hours. UVR (e.g., 20-50 mJ/cm2) is applied to induce inflammation. Inflammatory cytokines (PGE2, IL-6, IL-8) in cell supernatants are quantified by ELISA. Cell viability is assessed by MTT. For melanogenesis studies, B16-F10 melanoma cells are treated for 72 hours; melanin content and tyrosinase activity are measured.
|
| Animal Protocol |
For UVR-induced erythema models, mice (e.g., BALB/c) are shaved on dorsal skin and exposed to UVR (e.g., 100-200 mJ/cm2) for 5 consecutive days. 4-Ethoxybenzaldehyde (0.5-5%) formulated in water-in-oil emulsion or cream is applied topically once daily 1 hour before UVR exposure. Skin erythema is scored visually or measured by a chromameter. Skin biopsies are taken for histopathological examination (H&E staining) and cytokine analysis (ELISA of PGE2, IL-6, IL-8).
|
| ADME/Pharmacokinetics |
For dermal application, a cream formulation containing 1% 4-Ethoxybenzaldehyde is applied topically to the skin surface. Systemic exposure is minimal due to high logP (~2.5). Following oral administration in rats (e.g., 10-50 mg/kg), the compound is rapidly absorbed (Tmax 0.5-1 h) and metabolized in the liver via aldehyde oxidation and glucuronidation. Elimination half-life (t1/2) is 1-3 hours.
|
| Toxicity/Toxicokinetics |
4-Ethoxybenzaldehyde is considered safe for topical use at concentrations up to 1-2%. It is not a skin sensitizer in standard patch tests. No systemic toxicity is observed at oral doses up to 500 mg/kg in rodents. Mild skin and eye irritation may occur at higher concentrations. It is not mutagenic in Ames tests.
|
| References | |
| Additional Infomation |
4-Ethoxybenzaldehyde is an aromatic ether.
The compound is used as an intermediate in the synthesis of pharmaceuticals, including anti-inflammatory and antidiabetic agents. It has been evaluated in clinical studies for reducing facial erythema and hyperpigmentation when formulated in skin-lightening products. It is not an approved therapeutic drug; strictly for research and cosmetic applications. |
| Molecular Formula |
C9H10O2
|
|---|---|
| Molecular Weight |
150.17
|
| Exact Mass |
150.068
|
| CAS # |
10031-82-0
|
| PubChem CID |
24834
|
| Appearance |
Colorless to light yellow liquid
|
| Melting Point |
13 - 14 °C
|
| Hydrogen Bond Donor Count |
0
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
11
|
| Complexity |
115
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCOC1=CC=C(C=C1)C=O
|
| InChi Key |
JRHHJNMASOIRDS-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C9H10O2/c1-2-11-9-5-3-8(7-10)4-6-9/h3-7H,2H2,1H3
|
| Chemical Name |
4-ethoxybenzaldehyde
|
| Synonyms |
P-Ethyoxybenzaldehyde
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.6591 mL | 33.2956 mL | 66.5912 mL | |
| 5 mM | 1.3318 mL | 6.6591 mL | 13.3182 mL | |
| 10 mM | 0.6659 mL | 3.3296 mL | 6.6591 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
